Table 2.
Comparison of clinical outcomes between the two groups.
| Total (n = 364) | Group 1 (n = 295) | Group 2 (n = 69) | P-value | |
|---|---|---|---|---|
| Duration of Gn (days) | 10 (9–12) | 10 (9–11) | 12 (10–13) | < 0.001 |
| Total Gn dose (IU) | 1,800.0 (1,425.0–2,250.0) | 1,700.0 (1,375.0–2,175.0) | 2,175.0 (1,725.0–2,800.0) | < 0.001 |
| On the trigger day | ||||
| E2 (pg/mL) | 4,134.3 (2,749.0–6,424.0) | 4,552.4 (2,813.0–6,652.0) | 2,972.1 (2,400.8–4,865.2) | 0.001 |
| P (ng/mL) | 0.92 (0.65–1.31) | 0.96 (0.68–1.33) | 0.75 (0.57–1.19) | 0.014 |
| LH (IU/L) | 1.6 (0.7–3.0) | 2.0 (1.0–3.4) | 0.5 (0.3–0.7) | < 0.001 |
| Single ET (mm) | 5.0 (4.5–5.9) | 5.0 (4.5–5.8) | 5.5 (4.5–6.0) | 0.23 |
| No. of follicles ≥ 14 mm | 9 (8–12) | 9 (8–13) | 10 (8–11) | 0.84 |
| No. of oocytes retrieved | 14 (10–20) | 14 (10–20) | 13 (10–20) | 0.71 |
| IVF fertilization rate [n(%)] | 4,116/5,252 (78.4) | 3,276/4,236 (77.3) | 840/1,016 (82.7) | < 0.001 |
| ICSI fertilization rate [n(%)] | 424/473 (89.6) | 392/434 (90.3) | 32/39 (82.1) | 0.10 |
| Cleaved oocyte rate [n(%)] | 4,474/4,540 (98.5) | 3,612/3,668 (98.5) | 862/872 (98.9) | 0.40 |
| Available D3 embryo rate [n(%)] | 3,150/4,474 (70.4) | 2,578/3,612 (71.4) | 572/862 (66.4) | 0.004 |
| High-quality D3 embryo rate [n(%)] | 1,673/3,395 (49.3) | 1,370/2,721 (50.3) | 303/674 (45.0) | 0.012 |
| Blastocyst formation rate [n(%)] | 1,605/2,259 (71.0) | 1,349/1,890 (71.4) | 256/369 (69.4) | 0.44 |
| Available blastocyst rate [n(%)] | 1,396/1,605 (87.0) | 1,176/1,349 (97.2) | 220/256 (85.9) | 0.59 |
| High-quality blastocyst rate [n(%)] | 466/1,605 (29.0) | 387/1,349 (29.7) | 79/256 (30.9) | 0.48 |
| Embryo transfer cancelled [n(%)] | 216 (59.3) | 179 (60.7) | 37 (53.6) | 0.28 |
| Severe OHSS rate [n(%)] | 19 (5.2) | 11 (3.7) | 8 (11.6) | 0.008 |
| Biochemical pregnancy rate [n(%)] | 93/148 (62.8) | 70/116 (60.3) | 23/32 (71.9) | 0.23 |
| Clinical pregnancy rate [n(%)] | 83/148 (56.1) | 63/116 (54.3) | 20/32 (62.5) | 0.41 |
Gn, gonadotropin; E2, estrogen; P, progesterone; LH, luteinizing hormone; ET, endometrial thickness; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; OHSS, ovarian hyperstimulation syndrome.